Form 4: Boundless Bio Director James Christensen Receives Options

Director James Christensen was granted 32,000 stock options in Boundless Bio, Inc. as part of standard compensation.

Summary

• Director James Christensen received a grant of 32,000 stock options for Boundless Bio, Inc. (BOLD) common stock.
• The options have an exercise price of $1.40 per share.
• The grant date for these options is June 15, 2026.
• The options are set to expire on June 14, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• Dependence on the director's continued service for the vesting of the options.

Future Outlook

The options vest in substantially equal monthly installments over 12 months, or fully upon the next annual meeting if it occurs before June 15, 2027, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure director retention and alignment with company performance milestones.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a common practice among small-cap biotech firms to preserve cash while incentivizing board oversight.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options over the next 12 months or upon the next annual stockholders meeting.

Key Dates

Keywords

Boundless Bio, BOLD, Form 4, Insider Trading, Stock Options, Director Compensation